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906First-in-human study of the INCRAFT endograft
in patients with infrarenal abdominal aortic
aneurysms in the INNOVATION trial
Dierk Scheinert, MD, PhD,a Carlo Pratesi, MD,b Roberto Chiesa, MD,c Gioachino Coppi, MD,d
Jan S. Brunkwall, MD, PhD,e Gijs Klarenbeek, MD,f Ana Cebrian, PhD,f andGiovanni Torsello, MD,g
Leipzig, Germany; Florence, Milan, and Modena, Italy; Cologne, Germany; Diegem, Belgium; and
Münster, Germany
Objective: This multicenter, prospective, nonrandomized trial was undertaken to evaluate the first-in-human experience
with the INCRAFT endograft (Cordis Corporation, Bridgewater, NJ), an ultralow-profile trimodular bifurcate device for
the repair of abdominal aortic aneurysms.
Methods: Patients with asymptomatic infrarenal abdominal aortic aneurysms were eligible for enrollment in the trial.
Anatomic eligibility criteria included a proximal aortic neck at least 15 mm in length and up to 27 mm in diameter, and an
aortic bifurcation $18 mm in diameter. Iliofemoral access vessels were required to be large enough to accept the 14F
(4.7 mm) outer diameter of the delivery system. The primary efficacy end point was technical success, defined by successful
device deployment during the conclusion of the procedure at the desired location without a type I, III, or IV endoleak.
The primary safety end point was defined by the absence of a type I, III, or IV endoleak or a device- or procedure-related
major adverse event at the 1-month follow-up point.
Results: Over a 16-month period divided into two different phases, 57 men and three women with a mean age of 74.4 6
6.9 years were enrolled at three German and three Italian centers. A percutaneous approach was used in 36 patients
(60%). Successful graft deployment at the desired location was achieved in 59 patients (98%). A single patient had
successful deployment of the device although it was located more distally than planned. Technical success was achieved in
54 patients (90%); one patient had a type I endoleak, four had type IV endoleaks, and one had an endoleak of unde-
termined origin. The primary safety end point was met in 56 of the 58 patients (97%) with complete core laboratory data
at 1 month; two patients had type I endoleaks. There were no type III or IV endoleaks and no device or procedure-related
major adverse events at 1 month. No limb thromboses or stent fractures were noted on postoperative imaging studies and
no patient required rehospitalization, a secondary procedure, or open surgical conversion through 1 month of follow-up.
Conclusions: The INCRAFT endograft device holds promise as an innovative alternative to currently marketed devices and
broadens the eligibility for endovascular aneurysm repair. More definitive observations will be generated as longer-term
data from this trial become available. (J Vasc Surg 2013;57:906-14.)Historically, open surgical repair has been the gold stan-
dard method for preventing rupture of abdominal aor-
tic aneurysms (AAAs).1-3 Endovascular aneurysm repair
(EVAR) evolved in the early 1990s as a minimally invasive
treatment option. The use of EVAR increased over time,
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://dx.doi.org/10.1016/j.jvs.2012.09.079performed with this approach.4 The widespread applicability
of EVAR, however, is limited by current device technology
such that patients with challenging arterial anatomy are
either unsuitable for a minimally invasive approach or have
an increased risk of device-related complications over
time.5-8 Further, preprocedure imaging studies can only esti-
mate the aortoiliac length and diameter measurements
encountered with conformational changes that occur during
device implantation. Many commercially available devices
have limited ability for length adjustment on a real-time basis
to reliably conform to the specific anatomic configurations
encountered intraprocedurally in an individual patient.9-11
INCRAFT (Cordis Corporation, Bridgewater, NJ) is
a highly customizable, ultralow-profile stent graft that can
be efficiently deployed and accurately placed over a wide
range of vessel sizes and configurations.12 The device
employs an integrated delivery systemwith a 13F inner diam-
eter and 14F outer diameter (OD) to improve deliverability
through tortuous or small access vessels and reduce the
risk of delivery-related complications. The device has radi-
opaque maximum and minimum overlap marker bands
to facilitate precise in situ length adjustment during
Table I. Major eligibility criteria
Inclusion criteria
Age $18 years
Candidacy for open surgical repair of an AAA
AAA
Diameter $4.5 cm in women or $5 cm in men, or
Diameter >4 cm that has increased in size by 0.5 cm
within 6 months, or
Diameter $1.5 times aortic diameter measured
15 mm distal to lowermost main renal artery, or
Saccular configuration
Access vessel size compatible to a 14F (4.7 mm) outer
diameter delivery system
Proximal neck length $15 mm
Proximal neck diameter 20-27 mm
Iliac landing zone length $10 mm
Iliac landing sites diameter 9-18 mm
Length from lowest renal artery to distal landing zone
of $140 mm
Exclusion criteria
Aortic dissection
Inflammatory aneurysm
Ruptured aneurysm
Pararenal aneurysm
Suprarenal aorta 2 cm above lowest renal artery that is
not more than the nominal diameter of the aortic bifurcate
prosthesis
Suprarenal or infrarenal angulation of >60
Aortic bifurcation #18 mm in diameter
Aortic length (lowest renal artery origin to the
aortic bifurcation) <8.7 cm
Circumferential thrombosis and/or calcification $50% in the
suprarenal aorta, proximal aortic neck, or iliac landing zones
AAA, Abdominal aortic aneurysm.
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spectrumof anatomic variability encountered during a proce-
dure. Herein, we report the first in-human experience with
the INCRAFT device, assessing periprocedural outcome in
the first 60 treated patients.
METHODS
The INNOVATION study (multicenter, open-label,
prospective, nonrandomized study of INCRAFT in subjects
with AAAs) is a multicenter, prospective, nonrandomized
evaluation of the first in-human experience with the
INCRAFT device. Patients were enrolled in two phases. The
first phase of the trial included 25 patients at three German
sites, enrolled between March and November 2010. To
comply with regulatory requests for a larger sample size, the
protocol was revised to increase the study to 60 patients, and
three Italian sites were added. Between March and June
2011, 35 additional patients were enrolled in the second phase
of the trial. The trial was registered on ClinicalTrials.gov
(NCT01106391) andCompetent Authority approval was ob-
tained. The study was conducted in accordance with
the International Conference on Harmonization Guide-
lines, Good Clinical Practices, Declaration of Helsinki, ISO
14155-1, ISO 14155-2, and ethics committee requirements,
and all patients gave written informed consent prior to
participation.
On the basis of on site-determined measurements and
driven by the limited INCRAFT sizes available during this
study, patients were eligible for inclusion if the aneurysm
was $4.5 cm in diameter in women or $5.0 cm in men, or
$4.0 cm in either sex but had increased in diameter by
$0.5 cm over the prior 6 months. Patients were also eligible
if the aneurysm sac was$1.5 times the diameter of the refer-
ence aortic diameter measured 15 mm inferior to the distal
main renal artery or if the aneurysm was of saccular
morphology. The iliofemoral access arteries needed to be
suitable to accommodate a 14F profile delivery system (4.7
mm) and patients were excluded if the aortic bifurcation
was #18 mm in diameter. Major inclusion and exclusion
criteria are listed in Table I. Overall, 78 patients were con-
sented and screened, and 18 failed to meet the eligibility
criteria (23%), leaving 60 patients who underwent device
implantation and constituted the study population.
Device and the delivery system. The INCRAFT AAA
Stent graft System is a trimodular (one aortic bifurcate pros-
thesis main body and two iliac limb prostheses), bifurcated,
endovascular graft (Fig 1) that is preloaded into a delivery
system. The device is typically assembled from the three
components: the aortic bifurcate prosthesismain body and the
two iliac limb prostheses. If distal extension is desired, addi-
tional iliac limb prostheses can be deployed. The endograft is
constructedof a seamless, low-porosity,wovenpolyester fabric
tube, supported by a series of electropolished, laser-cut, self-
expanding nitinol stent rings along its entire length, each
sutured to the inner surface of the graft material. Radiopaque
markers are affixed to the device to facilitate fluoroscopic
positioning. The aortic bifurcate prosthesis has a short
infrarenal sealing endoskeleton and a proximal transrenal barestent with eight laser-cut barbs near the cranial apex of each
bare stent. The modular endograft components use suture
knots on the outer surface of the limb prostheses, acting as an
interlocking mechanism to decrease the risk of limb disunion.
The maximum and minimum radiopaque marker bands
facilitate precise fluoroscopic visualization and allow intra-
procedural length adjustment 2 to 3 cm between interlocking
modular components. At the time of the study, the aortic
bifurcate device was supplied in 26- and 30-mm diameters to
accommodate a range of aortic diameters from 20.0 to
22.9 mm and from 23.0 to 26.9 mm, respectively. Iliac graft
limbs were available in diameters of 13, 16, and 20 mm,
accommodating iliac vessels from 9.0 to 10.9, 11.0 to 13.9,
and 14.0 to 17.9 mm in diameter, respectively.
There are two variations of the delivery system; one for
the aortic bifurcate prostheses and one for the iliac limb pros-
theses. The delivery system for the aortic bifurcate prosthesis
has an inner diameter of 13F (14F OD) integrated sheath
introducer and does not employ a cap, simplifying the de-
ployment procedure. The delivery system for the iliac limb
prosthesis is similar to that of the aortic bifurcate prosthesis,
except that it is smaller in diameter (12.5FOD) and does not
have an integrated sheath introducer. The delivery system
facilitates controlled deployment at the intended location
(Fig 2). The prostheses are deployed by turning the handle
of the delivery system until the sheath begins to retract.
The barbs are unsheathed at the beginning of deployment,
Fig 1. INCRAFT endograft. A and B, Abdominal bifurcate and limb diameter and length. C and D, Radiographs
showing stent components and radiopaque markers.
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position of the main body device is possible. Repositioning
remains possible until the graft is unsheathed beyond the
contralateral side markers and the fixation release wire is
pulled to fully unconstrain the cranial aspect of the transrenal
stents.
Study end points. The study was designed with pri-
mary efficacy and primary safety end points. The primary effi-
cacy end point was technical success, defined by successful
device deployment at the desired location without a type I,
III, or IV endoleak at the conclusion of the procedure.
This definition is similar to that of the Society for Vascular
Surgery reporting standards, except that type IV endoleaks
and device deployment at other than the intended location
were included in the current study.13 Major adverse events
were defined as any death, myocardial infarction, stroke, or
occurrence of renal failure. The primary safety end point
was defined by the absence of a type I, III, or IV endoleak
or device- or procedure-related major adverse event (death,
myocardial infraction, stroke, or renal failure) at 1 month.
Secondary end points were measured at 1 month and in-
cluded stent fracture, graft thrombosis, and device explan-
tation. The length of intensive care unit stay, if any, as well as
the postprocedure and total length of hospital stay, was
recorded.Follow-up assessments. Vital signs and medications
were recorded at discharge and 1 month. Subsequent
follow-up visits will occur at 6 months, 12 months, and
annually thereafter up to 5 years and will be the subject of
subsequent communications, as data become available.
Follow-up imaging at 1 month included abdominal com-
puted tomography (CT), adding plain-film radiographywhen
the CT scan was inadequate to assess stent graft integrity or
stent fracture. Accuracy of endograft placement was assessed
by core laboratory measurement of the distance between the
graft edge marker of the aortic bifurcate prosthesis and
the lowest renal ostium on the 1-month CT scan. Any rein-
terventions or rehospitalizations were tabulated through 1
month, as were adverse events categorized by relatedness to
the device or to the procedure, severity (mild, moderate, or
severe), and whether they were serious or unanticipated.
Data analysis. No formal hypothesis testing was imple-
mented in this feasibility study; rather, descriptive statistics
alone were used. Patient source documentation was fully
monitored by site-independent clinical research associates
and assessed for completeness and accuracy. Any discrep-
ancies were resolved by queries with the site investigator or
designee. All CT images, plain film abdominal radiographs,
and procedure arteriograms were reviewed by the indepen-
dent core laboratory. Clinical events were adjudicated by
Fig 2. INCRAFT delivery system.
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independent experts not participating as investigators in
the trial. The CEC adjudicated all protocol-defined major
adverse events and type I, III, and IV endoleaks. Type II
endoleaks were adjudicated only when there was a discrep-
ancy between the site and the core laboratory assessment. A
Data and Safety Monitoring Board consisting of the three
CEC members was also established. The Data and Safety
Monitoring Board reviewed the data on a periodic basis to
determine the necessity of protocol modifications or, if
major safety issues arose, to recommend discontinuation of
the trial. Core laboratory and CEC-adjudicated data are
specified throughout, unless otherwise noted.
RESULTS
The 57men and three women were an average of 74.46
6.9 years of age. Patient baseline clinical characteristics are
summarized in Table II. Anatomic characteristics are summa-
rized in Table III. Mean aneurysm diameter was 52.6 6 9.2
mm, with a median of 52.2 mm (range, 34.7-101 mm).
Patients were enrolled for aneurysms, $45 mm if female
and$50mm if male, in 30 cases (50%); for AAAs$1.5 times
the diameter of the reference aorta in 26 cases (43%); for
AAAs that enlarged by $5 mm over 6 months in two cases
(3%); and for saccular AAAs in two cases (3%). Themaximum
AAA diameter was less than 40 mm in one patient (2%),
40-49 mm in 21 patients (35%), 50-59 mm in 31 patients
(52%), 60-69 mm in six patients (10%), and $70 mm in
one patient (2%). The configuration of the proximal neck
was parallel in 58 patients (97%), conical in one patient
(2%), and reverse-tapered in another patient (2%). Using
the Society for Vascular Surgery grading classification for
morphological risk, 45% of patients had hostile anatomy
that met criteria for the “severe” classification (Table IV;
Fig 3).14
The aortic bifurcate was introduced from the right side in
54 patients (90%). Percutaneous access with Perclose devices
(Abbott Vascular, Redwood City, Calif) was employed in 36
of 60 patients (58%), bilaterally in 34 patients (94%), and
unilaterally in two patients (6%), and the devices weresuccessfully delivered in all cases. A standard trimodular
configuration was used in 56 patients (93%), whereas four
patients (6.7%) had additional iliac extensions placed as
planned procedures to reach the desired distal landing loca-
tion. All 60 patients had successful deployment of the endog-
rafts without open surgical conversion or unintentional renal
or hypogastric artery occlusion. The endografts were
deployed at the intended aortic location in 59 patients
(98%); a single patient had successful deployment of the aortic
bifurcate prosthesis, although10mmdistal to the lowest renal
artery, and an aortic extension cuff was used to obtain addi-
tional sealing length. Additional endovascular procedures
were performed in seven patients (12%). Self-expanding
nitinol stent placement into a graft limb was attempted in
four patients (7%), each to prevent future problems within
a diseased or tortuous iliac artery; none of the stented limbs
had stenosis or kinking evident at the time of deployment.
Among the four stents, three were actually deployed; one dis-
lodged prior to deployment and was retrieved without subse-
quent placement of another stent. Therapeutic embolization
of side branches was performed in two patients (3%), one on
the inferior mesenteric artery and one on the hypogastric
artery. A renal stent was placed in one patient in whom preex-
isting 80% renal artery stenosis worsened after angioplasty.
The median postprocedure length of hospital stay was 5
days (range, 2-55 days). Additional technical details of the
procedures and hospitalizations are provided in Table V.
Endografts were placed with a high degree of accuracy,
with a mean distance between lowest renal artery and the
proximal graft edge markers of 3 mm (range, 4 to 15 mm,
without renal coverage). A core laboratory measurement
value of 4 mm was recorded, measuring the distance on
CT from the caudal point of the lowest renal ostium to the
caudal end of the second cranial graft-edge marker.
Although this measurement is accurate, it does not take
into account that the graft is positioned perpendicular to
the centerline and that the graft itself starts 0.0-1.0 mm
below themarker. The postdeployment images do not reveal
any renal artery obstruction in this patient. The patient with
deployment 15 mm below the lowest renal artery had the
device placed at this location because of unfavorable
anatomy in the cranial aspect of the proximal aortic neck.
Distally, the distance between the caudal graft-edge markers
and the hypogastric orifices averaged 12.2 mm, with mean
common iliac artery coverage of 79% by length. At the
conclusion of the procedure, 55 patients (92%) had no
evidence of type I, III, or IV endoleak (Table VI). With
the additional patient with graft deployment 10 mm below
the renal level, the primary efficacy end point of technical
success was achieved in 54 of 60 patients (90%; 95% confi-
dence interval [CI], 80%-96%).
The primary safety end point was met in 56 of 58
patients (97%; 95% CI, 88%-100%) with core laboratory
imaging available within the 1-month window. No patient
experienced a device- or procedure-related major adverse
event and 56 patients were free from type I, III, or IV endo-
leaks at 1month (Table VI). Type I endoleaks were noted in
two patients (3.3%). One patient had extensive aortic and
Table II. Patient baseline characteristic
Characteristic Mean 6 SD [95% CI] or % (number/total) [95% CI]
Age (mean), years 74.4 6 6.9 [72.6, 76.2]
Proportion male 95% (57/60) [86%, 99%]
Body mass index 26.7 6 3.1 [25.9, 27.5]
Smoking history
Current smoker 10% (6/60) [4%, 21%]
Former smoker 75% (16/25) [62%, 85%]
Diabetes
Insulin-dependent diabetes 5% (6/60) [1%, 14%]
Non-insulin-dependent diabetes 17% (10/60) [8%, 29%]
Hypertension 95% (57/60) [86%, 99%]
Hyperlipidemia 70% (42/60) [57%, 81%]
Renal status
Creatinine level, mg/dL 1.0 6 0.3 [1.0, 1.1]
<1.5 mg/dL 92% (55/60) [82%, 97%]
1.5-2.0 mg/dL 7% (4/60) [2%, 16%]
>2.0 mg/dL 2% (1/60) [0%, 9%]
Pulmonary status
No clinically evident lung disease 70% (42/60) [57%, 81%]
Clinically evident lung disease (COPD) 25% (15/60) [15%, 38%]
Other 7% (4/60) [2%, 16%]
Ischemic heart diseasea
Asymptomatic, normal ECG 55% (33/60) [42%, 68%]
History of arrhythmia 22% (13/60) [12%, 34%]
History of angina 13% (8/60) [6%, 25%]
History of myocardial infarcton 25% (15/60) [15%, 38%]
Previous CABG 15% (9/60) [4%, 21%]
PTCA 6 stent 10% (6/60) [0%, 9%]
Carotid/cerebral vascular disease
No disease 64% (38/59) [51%, 76%]
Asymptomatic stenosis 22% (13/59) [12%, 35%]
Transient ischemic attack 10% (6/59) [4%, 21%]
Completed stroke 3% (2/59) [0%, 12%]
Malignancy 15% (9/60) [7%, 27%]
Lower extremity arterial disease 8% (5/60) [3%, 18%]
CABG, Coronary artery bypass graft; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; PTCA, percutaneous
transluminal coronary angioplasty; SD, standard deviation.
aA single patient had unknown coronary status.
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patient had evidence of a type I endoleak on completion
arteriography, and placement of a Palmaz XL stent (Cordis
Corporation) into the proximal aortic neck diminished but
did not resolve the endoleak. The endoleak remained
evident on the 1-month CT imaging study, but was subse-
quently treated successfully after reinterventionwith balloon
inflation at the proximal attachment site. A type I endoleak in
a second patient was initially reported as a type II endoleak
by the site, but was subsequently adjudicated as a type I
endoleak by the CEC. This endoleak resolved after place-
ment of an aortic extender cuff and chimney graft to the
left renal artery, with endostapling at the proximal attach-
ment site. These two secondary interventions were per-
formed after the 1-month follow-up point.
Among the 60 enrolled patients, five procedure-related
serious adverse events occurred in four patients (7%). These
events included bleeding or hematoma formation at an
access site in two patients, one external iliac dissection, and
one lymphorrhea (Table VII). The iliac dissection occurred
on the side of main body introduction and was treated with
the deployment of an endograft limb to exclude the area ofinjury. There were five serious adverse events in four patients
that were not related to the device or the procedure. There
were no protocol-specified major adverse events, no
device-related serious adverse events, and no unanticipated
adverse device effects through 1 month of follow-up. Simi-
larly, no patient underwent open surgical conversion, and
there were no limb occlusions, endograft migrations,
secondary procedures, or rehospitalization through 1month
of follow-up. Eight access-related adverse events occurred in
seven patients (three percutaneous, four open), including
four bleeding events (three percutaneous, one open), three
lymphatic complications (all open), and one false aneurysm
formation (percutaneous). Among 54 patients with plain
abdominal radiographs evaluated at 1 month by the core
laboratory, no stent fractures or barb separations were
observed.
DISCUSSION
Although EVAR has become a desirable alternative to
traditional open surgical repair of AAAs, clinical outcome
continues to be suboptimal in patients with complex aortoil-
iac anatomy. Challenges for current devices fall into two
Table IV. Proportion of patients with severe
morphology as determined by core Laboratory
measurementsa
Anatomic measurement
Threshold for
severe gradeb
Proportion with
severe grade
Infrarenal neck angulation $60 5%
Proximal neck diameter >28 mm 2%
Proximal neck length <10 mm 17%
Right iliac artery sealing zone <10 mm 10%
Left iliac artery sealing zone <10 mm 13%
Right access artery diameter <7 mm 44%
Left access artery diameter <7 mm 46%
aPatients are enrolled based on site-determined measurements. These
measurements may differ from core laboratory measurements, accounting
for enrollees with certain core laboratory determinations outside of the
inclusion/exclusion criteria.
bAs defined by grade 3 (severe) anatomy, Ad Hoc Committee for
Standardization Reporting Practices in Vascular Surgery of the Society for
Vascular Surgery/American Association for Vascular Surgery.
Table III. Anatomic characteristics on the initial CT imaging study (Core Laboratory determinations)
Anatomic measurement Mean 6 SD (range) [95% CI]
Suprarenal aortic diameter, mm 24.2 6 2.0 (19.5-29.5) [23.7, 24.8]
Proximal neck diameter, cranial, mm 22.3 6 2.2 (17.0-29.5) [21.7, 22.8]
Proximal neck diameter, caudal, mma 23.0 6 2.4 (18.0-29.1) [22.4, 23.7]
Proximal neck length, mm 26.9 6 11.3 (5.0-49.8) [24.0, 29.8]
Suprarenal neck angulation, degrees () 14 6 8.3 (0.7-51) [12, 16]
Infrarenal neck angulation, degrees () 34 6 14 (7-67) [31, 38]
Maximum aneurysm diameter, mm 52.6 6 9.2 (34.7-101)b [50.2, 55.0]
Aortic bifurcation diameter, mm 20.6 6 4.6 (11.0-33.0) [19.4, 21.7]
Right distal iliac landing site diameter, mm 13.2 6 1.8 (9.0-18.0) [12.7, 13.6]
Left distal iliac landing site diameter, mm 13.9 6 2.5 (9.3-20.5) [13.2, 14.5]
Right access vessel minimum diameter, mm 7.2 6 1.3 (4.3-10.1) [6.9, 7.5]
Left access vessel minimum diameter, mm 7.1 6 1.5 (3.6-10.0) [6.8, 7.5]
CI, Confidence interval; CT, computed tomography; SD, standard deviation.
aMeasured 15 mm distal to the inferiormost main renal artery.
bA single patient had a 34.7-mm aneurysm that was measured by the site to be 41 mm and $1.5 times the reference aortic diameter.
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vessels, and reliable fixation and sealing within nonideal
proximal or distal attachment sites.15 These limitations
explain the continued necessity for open surgical repair in
approximately one-third of candidates.16 Long-term failures
of sealing and fixation and graft limb patency issues con-
tinue to occur in patients in whom the anatomic eligibility
indications for EVAR have been stretched.17 Lastly, most
marketed devices lack flexibility for intraprocedural adjust-
ments to accommodate inaccurate aortoiliac length and
diameter measurements from preoperative imaging studies,
requiring the use of additional components such as iliac
extender limbs and adjunctive stents to achieve satisfactory
aneurysm exclusion.10 The use of such adjuvant components
not only increases the duration and cost of the procedure,
but also increases the risk of early and late device-related
complications.18
Smaller, tortuous, and atherosclerotic iliofemoral access
vessels represent challenges to current devices. Navigationthrough such vessels can be associated with arterial injury,
intuitively more risky with larger-bore devices but still
common with even the newest devices.19-23 As well,
whether percutaneous access will ultimately be proven to
be beneficial over open femoral exposure, the approach
has been preferred by some physicians and can be more
difficult when the access vessels are small in relation to
the delivery system.24-26 The introducer sheath for the
Cook Zenith Flex device (Cook Medical, Bloomington,
Ind) ranges from 21F OD for the smallest-diameter main
body devices to 24.5F OD for the largest-diameter devices.
The Excluder trunk (W. L. Gore, Flagstaff, Ariz) is deliv-
ered through a sheath similar in size to the Zenith: either
20.5F OD for the smaller-size device or 23F OD for the
larger device. The Endologix AFX system (Endologix,
Irvine, Calif) uses a 19F OD sheath, whereas the original
Endologix Powerlink system used a 22F OD sheath. The
Cook Zenith Low Profile endograft (Cook Medical),
currently unavailable in the United States, is an 18F OD
system. Lastly, the Medtronic Endurant (Medtronic Inc,
Minneapolis, Minn) main body uses a somewhat smaller
sheathless delivery system, ranging from 18F OD for the
smaller sized devices to 20F OD for the larger devices.
Maximal coverage of the aorta within the proximal
aortic neck and common iliac arteries is desirable to decrease
the risk of endograft migration.27,28 It has long been known
that the proximal sutured anastomosis of a surgically placed
aortic graft should be placed as close to the renal orifices as
feasible; failure to do so is associated with an increased risk of
aneurysm formation above the level of the original graft.29
Compared with that after open surgical repair, the outcome
after endovascular repair may be more sensitive to changes
in vessel diameter.30 Whereas the danger of neck dilation
after open repair does not become evident until the vessel
dilates to a size where rupture is possible, even 2 or 3 mm
of aortic neck dilatation was associated with a requirement
for reinterventions in two studies.31,32 Although coverage
of the aortoiliac segment from the renal arteries to hypogas-
tric orifices is desirable, current devices are limited by the
Table V. Details of the procedure and hospitalization
Characteristic Mean 6 SD [95% CI]
Total procedure time, minutes 118 6 37 [109, 128]
Time to deploy device, minutes 42 6 23 [36, 48]
Fluoroscopy time, minutes 21 6 13 [18, 24]
Contrast administered, cc 127 6 67 [110, 145]
Procedural estimated blood
loss, cc
213 6 170 [165, 261]
Postprocedure length of hospital
stay, days
5.7 6 6.8 [3.9, 7.4]
CI, Confidence interval; SD, standard deviation.
Fig 3. Treated patients who fell within the severe morphological classification (screening study at top, post-treatment
on bottom). A, Severe neck angulation. B, Iliac tortuosity. C, Small external iliac arteries. Images were created with the
ImagineSCT medical imaging system for clinical trials.
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intended location. Imprecise delivery increases the need
for additional endograft components. In the standard risk
cohort of the Cook Zenith Investigational Device Exemp-
tion (IDE) trial, ipsilateral and contralateral iliac limb exten-
sions were used in 9.5% and 11% of patients, respectively.33
In the Ovation IDE trial, four or more components were
implanted in 18.6% of patients.34
The INCRAFT device was designed to address some
limitations of currently available devices. The device has an
ultralow-profile integrated delivery system with a 13F inner
diameter and 14F OD that can fit through tortuous and
small access vessels, improving the ease and speed of naviga-
tion and potentially reducing delivery-related complications.
The lower profile of the delivery system is of particular value
in patients with small or diseased iliofemoral access vessels,
and facilitates percutaneous introduction when desired. The
inability to accurately assess aortoiliac dimensions onpreoperative imaging studies is, in part, addressed by a broad
spectrum of length and diameter applicability for relatively
few sizes of graft components. As well, the portfolio of avail-
able device sizes was broadened after enrollment of the
current series of patients, and current INCRAFT devices
now accommodate proximal aortic necks ranging from 17
to 31 mm in diameter. The INCRAFT delivery mechanism
allows for in situ customized length adjustment features to
provide an individualized approach for patients. The
INCRAFT device has a partial repositioning feature to
improve proximal stent graft placement and fixation. The
Gore C3 delivery system has a repositioning feature, whereas
the Cook Zenith device does not offer this feature and
the Medtronic Endurant has only limited repositioning
capabilites.35,36
For the first 60 patients treated with the INCRAFT
device, feasibility and excellent periprocedural outcome
were documented. The primary efficacy and safety end points
were uniformlymet, and the rate of endoleakswas acceptable.
The accuracy of device deployment was high, with delivery of
the INCRAFT aortic bifurcate prosthesis an average of 3 mm
below the lowermost renal artery and deployment at the
intended location in 98% of patients. The use of additional
iliac extension limbs was necessary in only 7% of cases, likely
a function of placement accuracy and the broad range of
device overlap within the gate that provides the capacity for
intraprocedural length adjustment. The lower-profile delivery
system facilitated percutaneous access in the majority of
patients, without conversion to open femoral exposure in
any case. This outcome was achieved despite the particularly
large number of patients with small access vessels compared
Table VI. Incidence of endoleaksa
Type
Procedure
(n ¼ 60)
1 month (n ¼ 58)
Still evident Resolved New Totalb
I 1 1 0 1 2
II 13 11 2 21 32
III 0 0 0 0 0
IV 4 0 4 0 0
Undetermined 1 0 1 0 0
aEndoleaks at the conclusion of the procedure are site reported. Endoleaks
at 1 month are Core Laboratory reported and adjudicated by the Clinical
Events Committee.
bTotal endoleaks ¼ number still evident – number resolvedþ new endoleaks.
Table VII. Serious adverse events within 30 days of
implantation
Category of serious adverse event
No. (%)
of patients
No.
of events
Procedure related 4 (7) 5
Hematoma or bleeding at
puncture site
2 (3) 2
Pleural effusion 1 (2) 1
Lymphorrhea 1 (2) 1
External iliac artery dissection 1 (2) 1
Device related 0 0
Neither procedure nor device
related
4 (7) 5
Hypertension 1 (2) 1
Myocardial infarction 1 (2) 1
Dyspnea 1 (2) 1
Lymphocele 1 (2) 1
Claudication 1 (2) 1
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external iliac diameter was only 7 mm, a size that is at the
lower threshold specified by the instructions for use for
most currently marketed devices.17,37 Studies of other
devices report an increased risk of iliac graft limb thrombosis
when smaller-diameter graft limbs are used.7 As well, limb
occlusion rates have been high with newer, smaller-bore
devices. The Medtronic Endurant graft had limb occlusion
rates of 1.3% at 30 days and 2.7% at 12 months,38 and
a 7.7% thrombosis rate was observed at 12 months with the
Cook Zenith AAA Low Profile endograft.39 It remains
unclear whether these limb problems relate to a trade-off
between device profile and stent radial force or to an expan-
sion of use to patients with more challenging iliac
anatomy.38,40 Although 50% of limb occlusions have been re-
ported to occur within 30 days of endovascular repair,7,38 the
absence of INCRAFT limb complicationsmust be confirmed
by longer-term observations.
The 90% technical success rate observed in the current
study was less than what has been characteristic of recent
series, even when the series included patients with chal-
lenging anatomy.8,41-43 Although most reports use the
Society for Vascular Surgery Reporting Standards definition
of technical success, the current study added devicedeployment at the desired location and type IV endoleak to
the list of events that define success.13 Using the Society for
Vascular Surgery definition for technical success, one patient
with device deployment inferior to the intended site and four
patients with type IV endoleaks would not have triggered the
end point, resulting in a technical success rate of 98%, quite
similar to that of other contemporary reports.38 This differ-
ence in the definition of technical success, in large part,
accounts for the differences between this study and prior
reports. The 7% observed rate of type IV endoleaks in this
study is higher than one might expect, but is similar to the
12% rate reported in the Endurant US IDE trial. Whether
the higher rate of type IV leak in this study and in the Endur-
ant trial relates to greater rigor in postdeployment angiog-
raphy, better imaging equipment, or the fabric remains
undefined, but clinical sequelae have not been observed.
CONCLUSIONS
In summary, this feasibility study confirms excellent
short-term results with the INCRAFT device. The results,
however, must be considered within the context of the
short-term follow-up and the small study cohort of this first
in-human experience. Confirmation that the device meets
expectations must await the availability of longer-term data
in a larger group of patients. Nevertheless, the findings
suggest that the INCRAFT device holds promise as an inno-
vative alternative to currently marketed devices and broadens
the eligibility for EVAR. More definitive observations will be
generated as longer-term data from this study become avail-
able, as well as after the completion of other INCRAFT inves-
tigational trials currently in progress in the United States and
Japan and planned for Australia, New Zealand, and Europe.
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